Alcobra, a biopharmaceutical company focused on the development of a drug to treat ADHD, filed on Monday with the SEC to raise up to $17 million in an initial public offering. The Tel Aviv, Israel-based company, which was founded in 2008 and has not yet generated any revenue, plans to list on the NASDAQ under the symbol ADHD. Aegis Capital is the sole bookrunner on the deal. No pricing terms were disclosed.
